A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-12-17
Target enrollment:
Participant gender:
Summary
This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an
Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or
non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the
CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma
cancer cells. It delivers a dose of a modified toxin that kills these cells.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc. Molecular Templates, Inc.